Treatment of Leishmaniasis
For visceral leishmaniasis (VL) in the Indian subcontinent, combination therapy with either single-dose liposomal amphotericin B (5 mg/kg) plus miltefosine for 7-14 days OR paromomycin plus miltefosine for 10 days achieves 93-98% cure rates and represents the highest-grade evidence-based approach. 1
Visceral Leishmaniasis Treatment Algorithm
Geographic and Species-Specific Approach
Indian Subcontinent (L. donovani):
- First-line (Grade AI): Combination regimens achieve superior outcomes with fewer adverse events 1
- Regimen 1: Liposomal amphotericin B 5 mg/kg single IV dose + miltefosine orally for 7-14 days
- Regimen 2: Paromomycin 15 mg/kg IM daily for 10 days + miltefosine for 10 days
- Alternative (Grade BI): Miltefosine monotherapy 2.5 mg/kg/day for 28 days (weight-based dosing: 50 mg/day if <25 kg; 100 mg/day if 25-50 kg; 150 mg/day if >50 kg) 1
- Critical caveat: Recent reports show declining cure rates in this region, potentially due to emerging resistance 1
East Africa (L. donovani):
- Preferred: Liposomal amphotericin B at higher cumulative doses than Indian subcontinent 2, 3
- Miltefosine monotherapy shows moderate efficacy (75.6% cure rate in Ethiopia) 1
Mediterranean/South America (L. infantum):
- First-line: Liposomal amphotericin B 20 mg/kg cumulative dose for immunocompetent patients 2
- Limited data for miltefosine (Grade CIII) 1
HIV-Coinfected Patients
- Avoid miltefosine monotherapy - high relapse rates documented 1
- Recommended: Liposomal amphotericin B 30-40 mg/kg cumulative dose 2
- Secondary prophylaxis required until CD4 recovery maintained >6 months 2
Cutaneous Leishmaniasis Treatment Algorithm
Decision Framework: Simple vs Complex Disease
Simple CL (single/few small lesions, non-cosmetic areas, no mucosal risk):
- Local therapy preferred 2, 3
- Options: Intralesional pentavalent antimonials, cryotherapy, thermotherapy, topical paromomycin
- Key principle: Observation without treatment is acceptable if healing progresses; reassess periodically 3
Complex CL requiring systemic therapy 3:
- Multiple lesions (>4)
- Large lesions (>4 cm)
- Facial/joint involvement
- Species with mucosal risk (Viannia subgenus)
- Immunocompromised host
- Lymphatic/nodular involvement
Species and Geographic-Specific Systemic Treatment
Old World CL:
- L. major (Iran) - Grade BI: Miltefosine for 28 days (weight-based dosing as above) 1
- L. tropica/L. infantum - Grade CIII: Limited evidence; consider systemic therapy for complex cases 1
New World CL:
- L. panamensis (Colombia) - Grade BI: Miltefosine 20-28 days achieves >80% cure rates 1
- L. braziliensis (Brazil/Bolivia) - Grade BI: Miltefosine 20-28 days (75-80% cure) OR pentavalent antimonials 20 mg/kg/day for 20 days 1
- L. guyanensis (Brazil) - Grade BI: Miltefosine 20-28 days (71% cure) 1
- L. mexicana (Guatemala): Lower efficacy (50% cure); consider alternative agents 1
Alternative systemic agents (when miltefosine contraindicated/unavailable):
- Liposomal amphotericin B
- Pentavalent antimonials (sodium stibogluconate 20 mg/kg/day IM/IV)
- Pentamidine (for L. guyanensis/L. panamensis)
Mucocutaneous Leishmaniasis
Moderate disease (L. braziliensis, Bolivia) - Grade BII:
- Miltefosine 2.5-3.3 mg/kg/day for 28-42 days 1
- Critical point: Longer duration (42 days) shows better outcomes than 28 days 1
Severe disease:
- Systemic therapy mandatory
- Consider liposomal amphotericin B or pentavalent antimonials for extensive involvement
Post-Kala-Azar Dermal Leishmaniasis (PKDL)
India (L. donovani) - Grade BI:
Critical Safety Considerations
Miltefosine-Specific Warnings
- Absolute contraindication in pregnancy - teratogenic risk 1
- Mandatory contraception for 3 months post-treatment in women of childbearing potential
- Common adverse effects: Gastrointestinal (nausea, vomiting, diarrhea) - usually mild but can affect compliance 1
- Monitoring: Hepatic transaminases, creatinine (reversible elevations possible) 1
- Resistance concern: Long half-life creates risk of subtherapeutic levels if treatment discontinued prematurely 1
Treatment Failure Risk Factors
- Age <12 years (may require dose adjustment) 1
- Premature discontinuation due to rapid symptom improvement
- Geographic variation in parasite susceptibility
Monitoring and Follow-Up
During treatment:
- Clinical assessment of lesion healing (parasitologic testing not needed if healing) 3
- Debride eschar before local therapy 3
Post-treatment surveillance:
- CL patients: Nasal/oropharyngeal examination periodically up to 1-2 years 3
- Education: Signs of relapse (chronic nasal stuffiness, epistaxis, hoarseness, septal perforation) warrant immediate evaluation 3
- VL patients: Clinical cure assessment; relapse monitoring especially in immunocompromised
Special Populations
Children:
- Weight-based miltefosine dosing: 2.5 mg/kg/day for ages 2-11 years 1
- Higher failure rates documented; consider dose optimization 1
Immunocompromised (non-HIV):
- Liposomal amphotericin B preferred
- Consider secondary prophylaxis similar to HIV protocols
Pregnant women:
- Avoid miltefosine entirely
- Liposomal amphotericin B is treatment of choice when therapy cannot be delayed